APOCRINE CARCINOMA

Clinical trials for APOCRINE CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new APOCRINE CARCINOMA trials appear

Sign up with your email to follow new studies for APOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New hope for rare cancers: immunotherapy trial targets tumors regardless of origin

Disease control Recruiting now

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

Matched conditions: APOCRINE CARCINOMA

Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control

Last updated May 17, 2026 00:51 UTC

APOCRINE CARCINOMA

Get alerted when new APOCRINE CARCINOMA trials appear

New hope for rare cancers: immunotherapy trial targets tumors regardless of origin